Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765

Vertex Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Psoriasis

Treatments: Drug: VX-765

Study type: Interventional

Funder types: Industry

Identifiers

NCT00205465

VX04-765-301

Details and patient eligibility

About

To evaluate the safety and tolerability of VX-765 in subjects with chronic plaque psoriasis treated for 28 days.

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with chronic plaque psoriasis for at least 6 months
• Prior systemic therapy

Exclusion criteria

• Current or prior history of illness precluding use of immunomodulatory therapy.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind